Tuesday, March 17, 2015

The benefits of combination - Equipoise and Testosterone

This greatly anabolic and moderately androgenic steroid has an anabolic/androgenic ratio of 100:50. It has the molecular weight of 286.4132 g/mol at base and can be detected over a interval of four to five months and has an active life of nearly 14-16 days. the chemical formula of equipoise is C19H26O and its chemical name is 1,4-androstadiene-3-one,1 7b-ol). Cheaper than Deca Durabolin, Equipoise is admired for promoting muscle mass, aggression, and corpse strength. This execution enhancing medication does not result in excess water retention and aromatization. Equipoise is also useful for improving appetite and is rated very highly as a superior bulking cycle steroid. Equipoise is as anabolic and half androgenic as Testosterone and gets converted to Dihydronandrolone (DHN), a very peaceful androgen in comparison to Dihydrotestosterone (DHT).
This anabolic androgenic steroid stimulates the release of erythropoietin in the kidneys and promotes the count of red blood cells and the percentage of red blood cells (hemoglobin and Hematocrit) that translates into greater “pumps” during intense workouts.

If that was not all, muscle mass and corpse strength gains made with Equipoise (Boldenone Undeclynate) are more pronounced than with any other steroid or performance enhancing medication. Use of this steroid, for a period of six to ten weeks, is usually associated with promotion of solid, meaty muscle fiber when complemented with intense workouts, balanced and nutritious diet, and healthy lifestyle. This steroid is second to none for providing slow but steady strength gains and trait muscle mass. Muscles gained with Equipoise (Boldenone Undeclynate) are very refined and solid.

Male athletes usually administer Equipoise in weekly dosages of 200-600mg for about 8-12 weeks while female athletes may use this steroid in weekly dosages of 50-125mg for 6-10 weeks. Post cycle remedy with Clomid and Nolvadex is highly recommended towards the close of or at the end of an anabolic steroid cycle involving Equipoise (Boldenone Undeclynate) as one of the steroids or the only steroid. Anti-aromatase inhibitors such as Cytadren or Arimidex may even be used for making Equipoise cycles more tolerable. The addition of HCG is also recommended for avoiding a “crash”, particularly when Equipoise is administered during large cycles.

The combination of Equipoise and Testosterone is considered ideal for experiencing sustaining improvements in terms of lean corpse mass. Equipoise is usually stacked with Winstrol (Stanozolol), Oxandrolone, Testosterone enanthate, Testosterone Cypionate and Testosterone Propionate.

Equipoise is best injected at least once per week for maintaining steady blood levels. Men may use Equipoise in weekly doses of 400-600mg while female athletes may use it in weekly doses of 50-150mg.When overdosed or abused, Equipoise can effect in condition complications such as deepening of voice, irregular menstrual cycles, unnatural hair growth, and unusual hair loss. Equipoise (Boldenone Undeclynate) abuse may also cause acne, increased frequency of erections, unnatural hair growth, oily epidermis, enlarging clitoris or penis. Use of this potent steroid should be stopped and medical assistance should be sought if side effects like red-colored spots on body or inside the mouth or nose, sore throat and/or fever, vomiting of blood, bone pain, nausea, sore tongue, swelling of feet or lower legs, uncommon bleeding, unusual weight gain, black/tarry/light-colored stools, dark-colored urine are experienced after using Boldenone Undeclynate. Abuse of Equipoise may even lead to negatively-artificial lipid profile, virilizing effects in women, high degree of water/salt retention, gynecomastia, increased hair growth, acne, aggravation of male pattern baldness, and sexual side effects. Athletes should always emphasize on rotating injection sites on a regular basis and must follow healthy administration practices to avoid irritation, infection, and abscess formation.

No comments: